http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Mirum Pharmaceuticals to Present LIVMARLI® (maralixibat) Analyses and Host a Scientific Symposium at NASPGHAN 2022 Annual Meeting
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
-
Mirum Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals (MIRM) Highlights Data Demonstrating Impact of LIVMARLI
-
Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI® (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition
-
Mirum Pharmaceuticals (MIRM) Reports New Data at The International Liver Congress of the European Association for the Study of the Liver
-
Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)
-
Mirum Pharmaceuticals, Inc. (MIRM) to Showcase LIVMARLI Data at EASL and ESPGHAN Annual Congresses
-
Mirum Pharmaceuticals to Showcase LIVMARLI® (maralixibat) Data at EASL and ESPGHAN Annual Congresses
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors
-
Mirum Pharmaceuticals, Inc. (MIRM) Acquires Satiogen Pharmaceuticals
-
Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals
-
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
-
Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4, Provides Business Update
-
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
-
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End Business Results for 2021 and Host Conference Call on March 9, 2022
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference
-
Mirum Pharmaceuticals, Inc. (MIRM) Provides Business Update and Highlights Key 2022 Corporate Milestones
-
Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
-
Mirum Pharmaceuticals, Inc. (MIRM) Added to NASDAQ Biotechnology Index
-
Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index
-
Mirum Pharmaceuticals, Inc. (MIRM) LIVMARLI Show Improvements in Quality of Life Measures in Alagille Syndrome
-
LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at NASPGHAN Annual Meeting 2021
-
Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting
-
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Mirum Pharmaceuticals (MIRM) Sells Rare Pediatric Disease Priority Review Voucher for $110M
-
Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher
-
Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
-
Six-Year Natural History Comparison with Mirum’s (MIRM) LIVMARLI Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome
-
Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome
-
Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021
-
New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021
-
The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome
-
Mirum Pharmaceuticals, Inc. (MIRM) Announces FDA Approval of LIVMARLI
-
U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older
-
Mirum Pharmaceuticals (MIRM), Takeda (TAK) Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
-
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
-
Mirum Pharma (MIRM) Submits European MAA for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison
